secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001824293-26-000017
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports positive Phase 2a gene expression data for GRI-0621 in IPF
--------------------------------------------------------------------------

- Phase 2a gene expression data shows significant improvements in lung injury, fibroblast activation, and fibrosis-resolution genes vs placebo.
- Data support basement membrane repair and AT2-to-AT1 epithelial cell transition, suggesting lung regeneration.
- GRI-0621 met primary safety endpoint and multiple secondary endpoints; exploratory FVC improved vs standard of care.
- CEO states data exceed expectations, reinforcing potential as a disease-modifying therapy for IPF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000017/0001824293-26-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000017/val-20260128.htm
  HTML page:      https://secwatch.observer/filing/0001824293-26-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer